Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Brentuximab vedotin

Abstract

In August 2011 brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody–drug conjugate, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with Hodgkin's lymphoma and patients with systemic anaplastic large cell lymphoma (ALCL).

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Alley, S. C, Okeley, N. M. & Senter, P. D. Antibody–drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14, 529–537 (2010).

    CAS  Article  Google Scholar 

  2. 2

    Younes, A. CD30-targeted antibody therapy. Curr. Opin. Oncol. 23, 587–593 (2011).

    CAS  Article  Google Scholar 

  3. 3

    Wahl, A. F. et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 62, 3736–3742 (2002).

    CAS  PubMed  Google Scholar 

  4. 4

    Francisco, J. A. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458–1465 (2003).

    CAS  Article  Google Scholar 

  5. 5

    Doronina, S. O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotech. 21, 778–784 (2003).

    CAS  Article  Google Scholar 

  6. 6

    US Food and Drug Administration. FDA labeling information — Adcetris. FDA website [online], (2011).

  7. 7

    Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812–1821 (2010).

    CAS  Article  Google Scholar 

  8. 8

    Bartlett, N. L. et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann. Oncol. 18, 1071–1079 (2007).

    CAS  Article  Google Scholar 

  9. 9

    Gallamini, A. et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25, 3746–3752 (2007).

    CAS  Article  Google Scholar 

  10. 10

    Weihrauch, M. R. et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 65, 5516–5519 (2005).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Anas Younes, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

Anas Younas has received research support and/or honoraria from Seattle Genetics, Sanofi-Aventis, Novartis, Genentech, Plexxikon, Celgene, Gilead and Merck.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Younes, A., Yasothan, U. & Kirkpatrick, P. Brentuximab vedotin. Nat Rev Drug Discov 11, 19–20 (2012). https://doi.org/10.1038/nrd3629

Download citation

Further reading

Search

Quick links